TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06659549: A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Sponsor: Galimedix Therapeutics Inc · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 110 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT06659549 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06659549 Rescue Dossier →